Sermorelin is the synthetic analogue of the first 29 amino acids of endogenous GHRH and received FDA approval in 1990 for GH deficiency diagnosis and therapy. It stimulates physiological GH release through the pituitary's natural feedback system, making it one of the gentlest and most natural GH-stimulating approaches.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Sermorelin is the synthetic analogue of the first 29 amino acids of endogenous Growth Hormone Releasing Hormone (GHRH), which is the same segment that contains full biological activity. It is one of the oldest and most clinically validated GH secretagogues — it received FDA approval in 1990 (Geref Diagnostic) and has been used in both diagnostic testing for GH deficiency and therapeutic protocols. Sermorelin stimulates pituitary GH release through a purely physiological mechanism, making it a gentler and arguably more natural alternative to synthetic GH while preserving the body's own feedback regulation.
Mechanism of Action
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a physiological GH pulse through cAMP-mediated signaling. Unlike GHRPs, sermorelin does not interact with the ghrelin receptor or affect cortisol, prolactin, or appetite. Its mechanism is essentially a pure GHRH signal — the pituitary responds with a GH pulse proportional to the current somatostatin tone and existing pituitary reserve. This is a crucial distinction: sermorelin works through and respects the body's negative feedback mechanisms. If GH levels are already elevated, somatostatin will dampen the response, providing a natural ceiling. Sermorelin also stimulates the expression of GHRH receptor genes, potentially increasing the pituitary's sensitivity to future GHRH stimulation — a phenomenon not seen with exogenous GH administration.
Key Research
Sermorelin (Geref) received FDA approval in 1990 for growth hormone deficiency diagnosis and is one of the most clinically validated GH secretagogues. Multi-center clinical trials in children with idiopathic short stature demonstrated improved growth velocity. In adult GH deficiency, sermorelin restored IGF-1 levels and improved body composition. Long-term 12-month studies confirmed that unlike exogenous GH, sermorelin does not suppress the pituitary axis, and GH pulsatility resumes normally after discontinuation. The preservation of somatostatin feedback — documented in clinical studies — provides a natural ceiling for GH elevation, reducing risk of supraphysiological GH exposure.
The standard research and clinical dose is 200–500 mcg administered subcutaneously once daily, typically at bedtime. The bedtime dose takes advantage of the natural nocturnal GH peak and the fact that insulin levels are lowest (and therefore least inhibitory to GH release) during sleep. Some advanced protocols use twice-daily dosing (morning and bedtime) at 200 mcg per injection. Unlike the shorter-acting Mod GRF 1-29 (CJC-1295 no DAC), sermorelin can be used as a standalone GHRH (without a GHRP) for a gentler GH elevation, though combining with ipamorelin produces significantly stronger results. Cycles are typically 3–6 months given its gentler mechanism.
Foundational GH Protocol (beginner): Sermorelin 300 mcg subcutaneously at bedtime, daily for 6 months. Combined GHRH+GHRP Protocol: Sermorelin 300 mcg + Ipamorelin 200 mcg at bedtime nightly for 12–16 weeks for stronger GH amplification. Anti-Aging Maintenance: Sermorelin 200 mcg once nightly 5 days per week (weekdays only), indefinitely with periodic monitoring.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Sermorelin has one of the cleanest side effect profiles of any growth hormone secretagogue. The most common reported effects are mild injection site redness, flushing of the face, and a brief headache following injection — all transient and typically resolving within minutes to an hour. Water retention can occur but is less pronounced than with stronger GH-releasing protocols. Because sermorelin works through the pituitary's natural feedback system, it does not suppress endogenous GH production — the axis remains intact throughout and after the cycle. Antibody formation to sermorelin has been documented in a small percentage of users in clinical trials, but clinical significance appears minimal.
Storage & Handling
Store lyophilized sermorelin at 2–8°C protected from light. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. Sermorelin is considered relatively stable in reconstituted form compared to many other peptides. A 3 mg vial reconstituted with 3 mL BAC water yields 1 mg/mL (1,000 mcg/mL), with 1 unit on a U-100 syringe = 10 mcg.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
